Abdomino-Perineal Resection of Rectum | Surgery Treatments — Cost, Top Hospitals & Success Rates | MyMedicPlus

Abdominoperineal resection (APR), also known as Miles' operation, is a major surgical procedure involving the synchronous removal of the rectum, anus, anal sphincter complex, and surrounding mesorectal tissue through combined abdominal and perineal incisions. Unlike anterior resection which preserves the sphincter and allows bowel continuity, APR involves irrevocable excision of the entire anal sphincter mechanism, necessitating a permanent end colostomy through which the colon is brought out to the abdominal wall for the remainder of the patient's life.

APR is performed under general anaesthesia with the patient in the Lloyd-Davies (modified lithotomy) position to allow simultaneous abdominal and perineal access by two surgical teams. The abdominal phase involves mobilisation of the sigmoid colon and rectum, division of the inferior mesenteric vessels, total mesorectal excision (TME) — the cornerstone of modern rectal cancer surgery — and creation of a permanent sigmoid colostomy. The perineal phase involves wide excision of the anus, perianal skin, internal and external anal sphincters, and levator ani muscles, followed by perineal wound closure, often requiring myocutaneous flap reconstruction in patients who have received preoperative radiotherapy.

Extralevator APR (ELAPE) is an evolved technique that removes the levator ani muscles more completely from their pelvic sidewall attachment, providing a wider cylindrical specimen that reduces intraoperative bowel perforation risk and improves local recurrence rates in very low T3/T4 rectal cancers. Laparoscopic and robotic approaches to APR are now standard at specialist colorectal cancer centres, offering reduced blood loss, earlier bowel function return, shorter hospital stay, and equivalent oncological outcomes to open surgery.

Preoperative multimodal staging — rectal MRI (essential for mesorectal fascia involvement and sphincter invasion assessment), CT chest/abdomen/pelvis, and PET-CT in selected cases — precisely guides surgical planning. Neoadjuvant long-course chemoradiotherapy (50.4 Gy with concurrent capecitabine) is routinely administered for T3/T4 and node-positive low rectal cancers before surgery to downstage tumours, reduce local recurrence risk, and potentially convert cases requiring APR to sphincter-preserving surgery candidates.

The primary indication for APR is low rectal cancer where the tumour is so close to or involving the anal sphincter complex that sphincter-preserving surgery cannot achieve clear oncological margins (R0 resection). This applies to tumours within 1–2 cm of the dentate line, tumours invading the internal or external anal sphincters, and cases where neoadjuvant therapy has not achieved sufficient downstaging for sphincter preservation. APR is also appropriate when an adequate distal margin cannot be achieved with sphincter preservation, or when pre-existing sphincter dysfunction makes coloanal anastomosis unlikely to provide meaningful functional benefit.

Beyond primary rectal cancer, APR is indicated for locally recurrent rectal cancer involving the sphincter after prior sphincter-preserving surgery, anal canal squamous cell carcinoma that has failed or recurred after definitive chemoradiotherapy, extensive perianal Crohn's disease with severe intractable sepsis or fistulae having destroyed sphincter function, and for benign conditions including refractory fistula-in-ano with complete sphincter destruction, severe radiation proctitis, and cases where deep pelvic trauma or infection has rendered the sphincter non-functional.

Ideal candidates are patients with histologically confirmed low rectal or anal canal malignancy whose staging demonstrates tumour involvement of the sphincter complex precluding oncologically sound sphincter preservation, and who are medically fit for major pelvic surgery. Patients must be psychologically prepared to accept and manage a permanent colostomy — requiring dedicated preoperative counselling with a specialist stoma nurse who addresses siting, practical management, body image, and impact on relationships and daily life.

Contraindications include unresectable metastatic disease where surgery would not improve survival, severe cardiorespiratory comorbidity making prolonged general anaesthesia prohibitively risky, and patient refusal of permanent colostomy after full informed consent. Patients with impaired perineal wound healing due to prior pelvic radiotherapy, diabetes, or obesity require primary myocutaneous flap reconstruction (gracilis or gluteal flap) at the time of APR. Active perineal or pelvic sepsis should be controlled before elective resection.

Traditional open APR involves laparotomy for the abdominal phase and a separate perineal incision. At experienced colorectal cancer centres, laparoscopic APR using three to five small abdominal ports has replaced open surgery, demonstrating equivalent oncological outcomes in randomised trials (CLASICC, COLOR II) with significantly reduced perioperative morbidity. Robotic APR using the da Vinci system provides superior three-dimensional visualisation and articulated instruments in the narrow deep pelvis, particularly benefiting male patients where autonomic nerve-sparing is most challenging.

Extralevator APR (ELAPE) involves resecting the levator muscles from their pelvic sidewall attachment as a continuous cylindrical specimen, minimising the waist typically seen at the sphincter level in conventional APR and reducing margin positivity risk. Neoadjuvant long-course chemoradiotherapy administered six to eight weeks before surgery (German CAO/ARO/AIO-94 trial demonstrated reduction in local recurrence from 13% to 6% versus postoperative treatment) is standard for T3/T4 disease. In complete responders, the 'watch and wait' strategy with close surveillance is under active investigation at specialist centres as an organ-preservation alternative, with salvage APR for documented regrowth. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

APR with TME achieves curative resection (R0) in 80–90% of appropriately staged low rectal cancers at experienced centres. Five-year overall survival for Stage II low rectal cancer after neoadjuvant chemoradiotherapy and APR exceeds 75–80%, with Stage III disease achieving 50–65% with adjuvant chemotherapy. Local recurrence rates following modern TME-based APR are 5–8%, dramatically improved from historical rates of 30–40% before TME technique was established. For anal canal squamous cell carcinoma, salvage APR achieves five-year survival of approximately 40–50%.

Quality of life after APR is determined largely by adaptation to the permanent colostomy. Studies comparing APR versus anterior resection for low rectal cancer do not consistently show inferior quality of life when baseline sphincter function is poor — in these cases a reliable colostomy provides better functional outcomes than a poorly functioning low anastomosis with incontinence. Modern convex pouching systems, stoma irrigation techniques, and structured rehabilitation enable most patients to return to social activities, work, and travel within two to three months.

The most significant risk of APR is injury to the pelvic autonomic nerves responsible for bladder and sexual function. Urinary dysfunction (retention, incomplete emptying) occurs in 15–30% of patients, often requiring temporary catheterisation. Erectile dysfunction affects 30–70% of men and sexual dysfunction is common in women; rates are significantly lower with meticulous nerve-preserving technique. Perineal wound complications — particularly in patients having received preoperative radiotherapy — occur in 20–40%, ranging from superficial dehiscence to chronic perineal sinus requiring prolonged wound care or secondary surgical reconstruction.

Intraoperative risks include haemorrhage from the presacral venous plexus, ureteric injury, and bladder injury. Long-term complications include parastomal hernia (20–30%), stomal retraction or prolapse, and small bowel obstruction from adhesions. Phantom rectal sensations are experienced by some patients and typically resolve within months. Oncological risks include positive circumferential resection margins (pCRM) — a major predictor of local recurrence — reduced by careful TME technique, adequate preoperative staging, neoadjuvant downstaging, and ELAPE for very low tumours.

Postoperative hospital stay is seven to ten days. A urinary catheter remains in place for five to ten days while bladder function recovers. The permanent colostomy typically functions by postoperative day three to five, and stoma nurse education covering pouch application, dietary adjustments, and skin care is a critical component of the admission. Enhanced recovery after surgery (ERAS) protocols including early mobilisation and multimodal analgesia reduce stay and complications.

Oncological surveillance follows colorectal cancer guidelines: CEA every three months for two years then six-monthly to year five; CT chest, abdomen, and pelvis every six months for two years then annually to year five; colonoscopy at one year and every three to five years thereafter. Perineal wound review continues until complete healing (six to twelve weeks in irradiated patients). Sexual health counselling and pharmacological support are offered routinely. Pelvic floor physiotherapy addresses bladder rehabilitation. Return to work is typically possible at six to eight weeks after laparoscopic APR.

APR in the United States costs approximately $30,000–$60,000 for the surgical episode alone. The comprehensive colorectal cancer treatment pathway including neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy commonly exceeds $100,000–$150,000. In the United Kingdom under private care, APR costs £15,000–£25,000 for surgery, with chemoradiotherapy additional. These figures represent significant financial burdens in systems without universal coverage.

JCI-accredited specialist colorectal cancer centres in India (Tata Memorial Hospital, Apollo, Fortis) provide laparoscopic and robotic APR at $5,000–$12,000. Comprehensive treatment packages including neoadjuvant chemoradiotherapy, surgery, and pathology analysis cost $15,000–$30,000 — representing savings of 70–80% versus US prices. Thailand and Turkey offer comparable packages. Patients must plan for an eight to twelve week stay when neoadjuvant therapy is included before surgery. International patients should factor in the cost of pre-operative testing, post-operative accommodation during recovery, translation services where required, and travel insurance including medical evacuation cover when planning overseas medical treatment.

For patients achieving clinical complete response to neoadjuvant chemoradiotherapy, a 'watch and wait' organ-preservation strategy with intensive surveillance is available at specialist centres. The OPRA trial demonstrated 40–50% of complete responders can potentially avoid surgery, with organ preservation in approximately 50–70% at five years using close surveillance and salvage APR for regrowth. This approach remains experimental outside specialist research settings.

Transanal local excision (TEM or TAMIS) offers an alternative to APR for carefully selected early T1 rectal cancers with favourable histology where lymph node metastasis risk is very low. For unresectable or metastatic disease, palliative loop colostomy without APR provides symptom relief. For anal canal squamous cell carcinoma, definitive chemoradiotherapy (Nigro protocol) achieves durable local control and cure in 60–70% of patients, reserving APR only for salvage of persistent or recurrent disease.